Anti-Mouse CD70 – Biotin

Anti-Mouse CD70 – Biotin

Product No.: C2404

[product_table name="All Top" skus="C2404"]

- -
- -
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
TNFSF7, KI-24 antigen, CD27 Ligand, CD27L

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Host Species
BALB/c mouse B lymphoma A20.J2
Product Concentration
0.5 mg/ml
This biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
Country of Origin
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this FR70 antibody for staining cells in flow cytometry is ≤ .25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Reported Applications For Relevant Conjugates ?

For specific conjugates of this clone, review literature for suggested application details.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


FR70 activity is directed against mouse CD70.
CD70, a type II transmembrane glycoprotein of the TNF family with cytokine activity, is the ligand for the CD27 receptor1. Mouse CD70 (mCD70) has a potent co-stimulatory effect on T cell proliferation1 and acts as an immune-checkpoint2. In mouse, but not in humans, the CD70-CD27 axis mediates a negative feedback system that enables the immune system to modulate hematopoiesis2. Additionally, CD70-CD27 interactions are important to the formation of memory and plasma B cells. Immunotherapies that aim to eradicate tumor cells by targeting CD70 overexpression are being developed2. FR70 inhibits mCD70 binding to mCD27-Ig, a recombinant soluble form of mCD271, as well as to mCD27 in vitro3,4 and in vivo5. FR70 was produced by immunizing an F344/DuCrj rat with A20 cells and fusing the splenocytes with P3U1 cells to create hybridoma lines1. HAT selection was performed, and FR70 was identified by its strong reactivity against mCD70-BHK21 cells. Blocking with FR70 can prolong graft acceptance6,7. When mouse cardiac allogenic graft recipients are treated with FR70, tolerogenic dendritic cells and T regulatory cells are induced, resulting in decreased cytotoxic T lymphocyte proliferation as well as long-term graft acceptance6. Blocking with FR70 also prolongs mouse corneal graft survival7.
Antigen Distribution
Mouse CD70 is transiently expressed on the surfaces of antigen-activated B and T cells, natural killer cells, and mature dendritic cells. CD70 is also aberrantly expressed on malignant cancer cells

Antigen Details

NCBI Gene Bank ID
Research Area
Costimulatory Molecules

References & Citations

1. Oshima H, Nakano H, Nohara C, et al. Int Immunol. 10(4):517-526. 1998.
2. Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. J Exp Clin Cancer Res. 41(1):12. 2022.
3. Mahmud SA, Manlove LS, Schmitz HM, et al. Nat Immunol. 15(5):473-481. 2014.
4. Kuka M, Munitic I, Giardino Torchia ML, et al. J Immunol. 191(5):2282-2289. 2013.
5. Ballesteros-Tato A, León B, Lee BO, et al. Immunity. 41(1):127-140. 2014.
6. Zhao J, Que W, Du X, et al. Front Immunol. 11:555996. 2021.
7. Narimatsu A, Hattori T, Usui Y, et al. Exp Eye Res. 199:108190. 2020.
8. Wensveen FM, Unger PP, Kragten NA, et al. J Immunol. 188(9):4256-4267. 2012.
9. Tewalt EF, Cohen JN, Rouhani SJ, et al. Blood. 120(24):4772-4782. 2012.
10. Ho PC, Meeth KM, Tsui YC, et al. Cancer Res. 74(12):3205-3217. 2014.
Flow Cytometry

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.